О журнале |  Редакционная коллегия |  Архив | Текущий номер |  Подписка |  Авторам     


Журнал "Клиническая геронтология"

ЭФФЕКТИВНОСТЬ РАЗЛИЧНЫХ ГРУПП ФАРМПРЕПАРАТОВ В ПРОФИЛАКТИКЕ РЕЦИДИВОВ ДИВЕРТИКУЛИТА ТОЛСТОЙ КИШКИ (В помощь практическому врачу)

С.В. Левченко

Левченко Светлана Владимировна, ассистент кафедры поликлинической терапии.

Тел.: 8(495) 6233660. E–mail: sv_levchenko@list.ru.

Московский государственный медико-стоматологический университет им. А.И. Евдокимова

Представлен анализ результатов исследований последних лет по оценке эффективности различных групп фармакологических препаратов в противорецидивной терапии дивертикулита.

Ключевые слова: дивертикулит, салицилаты, пробиотики, бутират, противорецидивное  лечение, профилактика рецидивов

THE EFFECTIVENESS OF THE DIFFERENT GROUPS OF PHARMACEUTICALS IN anti- recurrent treatment of COLON diverticulitis (Practitioners assistans)
S.V. Levchenko

Levchenko S.V. , assistant of department of policlinic therapy. Tel..: 8(495) 6233660. E–mail: sv_levchenko@list.ru.

MSMSU n.a. A.I.Evdokomov

The article presents the analysis of the recent studies results of different variants of anti- recurrent treatment of colon diverticulitis with the assessment of the effectiveness of therapy

 Keywords: diverticulitis, salicylates, probiotics, butyrate, anti- recurrent treatment, relapse prevention

 

Литература

  1. Daniels L.1., Budding A.E., de Korte N., Eck A., Bogaards J.A., Stockmann H.B., Consten E.C., Savelkoul P.H., Boermeester M.A. Fecal microbiome analysis as a diagnostic test for diverticulitis// Eur. J. Clin. Microbiol. Infect. Dis. 2014. Jun 4. Epub ahead of print.
  2. Dughera L.1., Serra A.M., Battaglia E., Tibaudi D., Navino M., Emanuelli G. Acute recurrent diverticulitis is prevented by oral administration of a polybacterial lysate suspension// Minerva Gastroenterol. Dietol. 2004. Jun . Vol.50. №2. P.149-153.
  3. Gatta L.1., Di Mario F., Curlo M., Vaira D., Pilotto A., Lucarini P., Lera M., Enkleda K., Franz? A., Scarpignato C. Long-term treatment with mesalazine in patients with symptomatic uncomplicated diverticular disease// Intern. Emerg .Med. 2012. Apr. Vol. 7. №2. P.133-137. doi: 10.1007/s11739-011-0509-7. Epub 2011. Jan 29.
  4. Groschwitz K.R., Hogan S.P. Intestinal barrier function: molecular regulation and disease pathogenesis// J. Allergy Clin. Immunol. 2009. Vol. 124. P. 3-20.
  5. Gross V. Aminosalicylates. Dig Dis. 2012. Vol.30. №1. P.92-99. doi: 10.1159/000335906. Epub 2012. May 3.
  6. Humes D.J., Spiller R.C. Review article: The pathogenesis and management of acute colonic diverticulitis// Aliment. Pharmacol. Ther. 2014. Feb. Vol.39. №4. P.359-370. doi: 10.1111/apt.12596. Epub 2014 .Jan 6.
  7. Iosca N.1., Ferrieri A. The rifaximin therapy and prophylaxis of episodes of acute diverticulitis// Recenti Prog. Med. 1993. Jan. Vol.84. №1. P.49-53.
  8. Jackson JD, Hammond T.  Systematic review: outpatient management of acute uncomplicated diverticulitis// Int. J. Colorectal. Dis. 2014. Jul. Vol.29. №7.P. 775-781. doi: 10.1007/s00384-014-1900-4. Epub 2014. May 25.
  9. Jamal Talabani A., Lydersen S., Endreseth B.H., Edna T.H. Major increase in admission- and incidence rates of acute colonic diverticulitis// Int. J. Colorectal. Dis. 2014. Aug. Vol.29. №8. P.937-945. doi: 10.1007/s00384-014-1888-9. Epub 2014. May 8.
  10. Krokowicz L., Stojcev Z., Kaczmarek B.F., Kociemba W., Kaczmarek E., Walkowiak J., Krokowicz P., Drews M., Banasiewicz T. Microencapsulated sodium butyrate administered to patients with diverticulosis decreases incidence ofdiverticulitis--a prospective randomized study// Int. J. Colorectal. Dis. 2014. Mar. Vol.29. №3. P. 387-393. doi: 10.1007/s00384-013-1807-5. Epub 2013. Dec 18.
  11. Lanas A.1., Ponce J., Bignamini A., Mearin F. One year intermittent rifaximin plus fibre supplementation vs. fibre supplementation alone to prevent diverticulitis recurrence: a proof-of-concept study//  Dig. Liver. Dis. 2013. Feb. Vol.45. №2. P.104-109. doi: 10.1016/j.dld.2012.09.006. Epub 2012. Oct 23.
  12. Raskin J.B., Kamm M.A., Jamal M.M., M?rquez J., Melzer E., Schoen R.E., Szal?ki T., Barrett K., Streck P.  Mesalamine Does Not Prevent Recurrent Diverticulitis in Phase 3 Controlled Trials// Gastroenterology. 2014. Jul 16. pii: S0016-5085(14)00900-7. doi: 10.1053/j.gastro.2014.07.004. Epub ahead of print.
  13. Tursi A. Efficacy, safety, and applicability of outpatient treatment for diverticulitis// Drug. Healthc. Patient. Saf. 2014. Mar 31. Vol.6. P.29-36. doi: 10.2147/DHPS.S61277. eCollection 2014.
  14. Tursi A. New physiopathological and therapeutic approaches to diverticular disease: an update// Expert. Opin. Pharmacother. 2014. May.  Vol. 15. №7. P.1005-1017. doi: 10.1517/14656566.2014.903922. Epub 2014. Mar 31.
  15. Tursi A.1., Di Mario F., Brandimarte G., Elisei W., Picchio M., Loperfido S., Dal Bo' N., Ferrara F,, Marcello R., Heras Salvat H., Scarpignato C. Intermittent versus every-day mesalazine therapy in preventing complications of diverticular disease: a long-term follow-up study// Eur. Rev. Med. Pharmacol. Sci. 2013. Dec.17. №23. P.3244-3248.
  16. Tursi A.1., Elisei W., Giorgetti G.M., Inchingolo C.D., Nenna R., Picchio M., Maiorano M., Penna A., Lecca P.G., Brandimarte G. Effectiveness of different therapeutic strategies in preventing diverticulitis recurrence// Eur. Rev. Med. Pharmacol. Sci. 2013. Feb. Vol.17. №3. P.342-348.
  17. Tursi A1, Joseph RE, Streck P. Expanding applications: the potential usage of 5-aminosalicylic acid in diverticular disease// Dig. Dis. Sci. 2011. Nov. Vol.6. №11. P.3112-3121. doi: 10.1007/s10620-011-1731-x. Epub 2011. May 13
  18. Viniol A., Keunecke C., Biroga T., Stadje R., Dornieden K., B?sner S., Donner-Banzhoff N., Haasenritter J., Becker A . Studies of the symptom abdominal pain-a systematic review and meta-analysis// Fam. Pract. 2014. Jul 1. pii: cmu036. Epub ahead of print.
  19. Weisberger L.1., Jamieson B. Clinical inquiries: How can you help prevent a recurrence of diverticulitis?//  Fam .Pract. 2009. Jul. Vol. 58.№7. P.381-382.


Programming & design
by I.S.0pаrin